Ildong (CEO Yoon Woong-seop) announced on the 24th that it has obtained a patent for domestic substances for ID110521156, a new drug candidate for type 2 diabetes treatment under development.
​
ID110521156 is a drug in the GLP-1 receptor agonist family that acts as a analog to the Glucagon-like peptide-1 (GLP-1) hormone that regulates blood sugar levels by inducing insulin secretion. GLP-1 hormones are produced and secreted in β cells of the pancreas and are known to be involved in the secretion and blood sugar control of insulin in the body, digestive organ exercise, and appetite suppression.
​
ID110521156 has the same function as GLP-1 hormone and has a low molecular weight c